Oncology · NSCLCTrial Updateclinicalmid-term

Divarasib Study in Untreated Advanced NSCLC Shows Promise for Safety and Efficacy

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/14/2026, 12:30:44 PM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing trial of divarasib in advanced NSCLC could significantly influence treatment protocols and competitive positioning in oncology. Positive outcomes may enhance Hoffmann-La Roche's portfolio and market share in a critical therapeutic area. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 13 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should monitor divarasib's trial outcomes to assess its potential impact on current NSCLC treatment strategies. The strongest clinical anchor is A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Meta (ClinicalTrials.gov), sub-indication match (lung cancer); entity match (roche). In lung cancer, 4 regulatory and 4 competitive items passed relevance filtering for Roche.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sub-indication match (lung cancer); entity match (roche). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial could position divarasib as a significant player in the NSCLC treatment landscape, especially if combined therapies prove effective.

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer (MHRA). Sponsor/company relevance (Roche); Patient population match (advanced). Relevant agencies in corpus: MHRA, FDA. The trial's outcomes will be crucial for future regulatory submissions and could affect label indications for divarasib in NSCLC.

Key Risks

Elevated medium regulatory exposure for Roche could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Roche through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

Successful trial results could lead to increased adoption of divarasib, impacting revenue streams and market share in the oncology sector.
Lead sponsor: Hoffmann-La Roche. The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Upside for Roche may improve if A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cel (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Oncology · KRAS G12C-Positive Non-Small Cell Lung Cancer · Trial Update · This trial positions divarasib as a potential alternative to established therapies like pembrolizumab and nivolumab for KRAS G12C-positive NSCLC.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results on safety and efficacy, as well as potential combination therapy outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Roche); Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Roche); Regulatory pathway relevance (nda)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Meta
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (roche)
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cel
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (roche)
FDA document
View source
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govlow relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govlow relevance
Sponsor/company relevance (Roche)
FDA document
View source
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
ClinicalTrials.govlow relevance
Sponsor/company relevance (Roche)
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (roche)
Divarasib Study Targets KRAS G12C-Positive NSCLC Post-Chemoimmunotherapy
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
Neladalkib (NVL-655) shows promise in Phase 3 trial for ALK-positive NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedmedium relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedlow relevance
Sponsor/company relevance (Roche)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Roche
NSCLC treatment landscape

Commercial impact

medium

Successful trial results could lead to increased adoption of divarasib, impacting revenue streams and market share in the oncology sector.

Regulatory impact

medium

The trial's outcomes will be crucial for future regulatory submissions and could affect label indications for divarasib in NSCLC.

What to watch

Key milestones include interim results on safety and efficacy, as well as potential combination therapy outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.